



Therapeutic Vaccines: Why Have They Succeeded in Some Diseases and Failed in Others?

Mubashra Inam^{1*} | Kiran Rehman¹ | Rabiya Atta¹

¹Department of Allied Health Sciences, Superior University, Lahore, Pakistan

*Correspondence: Mubashra Inam (mubashrainam@gmail.com)

Citation: Inam M, Rehman K, Atta R. Therapeutic Vaccines: Why Have They Succeeded in Some Diseases and Failed in Others? J Biomol Pathog Ther. 2026;2(1):61-63.

Received: 12 February, 2026

Revised: 27 February, 2026

Accepted: 06 March, 2026

Published: 10 March, 2026

ABSTRACT

Background: Therapeutic vaccines generate or restore antigen-specific immunity, providing a unique clinical approach as compared to prophylactic vaccination. Although therapeutic vaccines have intermittent efficacy in different diseases, their optimistic response is reported in some infectious diseases whereas, insignificant efficacy in many chronic and immune-dysregulated malignancies. This questions the underlying biological and translational determinants and seek scientific explanations for these divergent outcomes. Therapeutic vaccines have been linked with well-characterized conserved target antigens, partially preserved immune competence, and disease settings that allow effective immune activation, which predetermines the success of therapeutic vaccines. In contrast, failure of these vaccines is often associated with antigenic variability, immune exhaustion or tolerance, prevailing immunosuppressive mechanisms, and recalcitrant disease microenvironments that impair effective immune interactions. Additional complications include vaccine platforms, poor adjuvants as well as concerns related to design of clinical trials like poor endpoints and poor patient stratification. Immunology, biomolecular profiling and vaccine engineering technologies have elucidated these challenges and identified ways of overcoming them. The translational efficacy can be improved by integrating therapeutic vaccines with immune-modulating factors, selection of targeted antigens, and the use of biomarkers to guide the clinical process. It is essential to define success and failure to guide the development of next-generation therapeutic vaccines rationally.

Keywords: Vaccines, Therapeutic; Immunotherapy; Antigens, Neoplasm; Immune Tolerance; T-Lymphocyte Exhaustion; Tumor Microenvironment; Biomarkers

Therapeutic vaccines are intended to induce, replace, or recreate antigen-specific immunity, in previously affected individuals ¹. This strategy differs from prophylactic vaccination, which is active in immunologically naïve hosts and prevents infection or the development of a disease. From pathophysiological perspective, therapeutic vaccines have to fight with the already existing pathological processes including immune tolerance, chronic inflammation, immune exhaustion, and tissue-specific immunosuppression ². These elements place great biological limits resulting in diverse clinical responses in terms of therapeutic vaccine efficacy. Experimental evidence has demonstrated that alterations in cellular signaling and immune-related pathways significantly influence disease progression and therapeutic responsiveness ³.

Therapeutic vaccines have been explored in numerous disease models, such as chronic viral infection, cancer, autoimmune diseases and neurodegenerative disorders ⁴. Not all of these vaccines have shown a significant clinical benefit or immunogenicity in spite of an encouraging preclinical profile. This inconsistency interrogates the viability of therapeutic vaccination, demonstrating a lack of understanding about disease-specific immune dysregulation ⁵. Notably, failure of therapeutic vaccines is often associated with discrepancies between vaccine design and biology of disease as opposed to inherent constraints of immunization as a therapeutic agent. Environmental and epigenetic modifications also influence disease phenotypes and therapeutic outcomes across experimental models ^{6,7}. To understand the reasons why therapeutic vaccines are effective in certain diseases and fail in others, this viewpoint provides a combined approach on the consideration of antigen biology, host immune status, disease pathogenesis and translational strategy ⁸.

Antigen Stability: Comparative analysis of reported literature indicates that there are number of persistent success factors of therapeutic vaccines across various diseases. Antigen definition and stability is one of the important factors ⁴. Incidents of diseases where therapeutical vaccines have been shown to be advantageous, usually entail well-conserved, antigens that are fundamental to the survival of pathogens or the

sustenance of cancers ⁶. Conversely, disease with a high degree of antigenic variation or antigen evolution leads to vaccine failure since vaccination-induced immune responses can become useless due to antigen escape.

Host-Immune Competence: Another significant determinant is the host immune competence. Therapeutic vaccines have higher chance of success when they are used in an environment with intact immune effector function ⁵. T-cell responsiveness and antigen presentation pathways may not be completely compromised in early-stage cancer or controlled chronic infections to allow vaccine-generated immunity ⁷. In contrast, severe cases of malignancies and chronic infections are often characterized by severe immune depletion, dominance by regulatory T-cells and dysfunctional antigen-presenting cells all of which restrict the effect of vaccines ².

Disease Microenvironment: Microenvironment of diseases is also a critical factor. Immunosuppressive tumor microenvironments or tissues with chronic inflammation enriched with inhibitory cytokines and checkpoint molecules are capable of actively inhibiting vaccine-induced immune responses ⁹. Also, vaccine platform and adjuvant are significantly correlated with treatment outcome. The platforms that do not produce strong cellular immunity or long-term memory responses are less likely to create clinical benefit in therapeutic scenarios ¹⁰.

Lessons from Clinical Failures: The prime reason for the failure of therapeutic vaccination lies in the fact that similar approaches are being used to cure biologically diverse diseases ¹¹. Cancers and chronic infections often develop advanced immune evasion strategies, such as antigen downregulation, tolerance induction, and local immune environment remodeling ¹². Vaccination will be inconsistent in such environments to counteract immune malfunction. A combination therapy involving therapeutic vaccines and immune checkpoint inhibitors, cytokine regulation, or metabolic reprogramming may be required to have the immune responsiveness restored ¹³. Moreover, the clinical trial designs such as the heterogeneity of patients, wrong endpoints, and the absence of biomarker-based stratification, led to poor consistency of efficacy signals and premature rejection of potentially effective strategies.

A Framework for Rational Design: The lack of synergistic results in therapeutic vaccine development highlights the significance of designing vaccine with disease-specific immunopathogenesis ¹⁴. In contrast with prophylactic vaccination, therapeutic immunization does not depend on generalized immune activation but has to go around established mechanisms of immune regulation and evasion ¹⁵. Diseases that are successfully treated with therapeutic vaccines are likely to have a number of common characteristics: stable and biologically relevant antigens, limited immune evasion and host immune systems that can generate effective effector responses ¹⁶. Such conditions are not always universal and they have to be properly considered while developing the vaccine.

Future Directions: New biomolecular profiling and systems immunology technologies have enhanced the capability of describing disease-specific immune landscapes and identifying predictive biomarkers. The tools allow rational patient selection and optimization of the vaccine timing, dose, and formulation ¹⁷. Neoantigen-based vaccines and other forms of personalized antigen will provide exciting solutions to overcome the antigenic heterogeneity, especially in cancer research. Moreover, new adjuvants and delivery vectors that can enhance antigen delivery and T-cell priming can be used to overcome shortcomings of previous vaccine technologies ¹⁸.

Conclusion

To sum up, therapeutic vaccines cannot be considered as a single set of intervention instead they are disease-specific immunological weapons, and their success is predetermined by a justified choice according to the pathogenesis and the condition of the host immunity ¹⁹. The insight into the failure of therapeutic vaccines in certain diseases and their success in others provide essential guidelines for future vaccine development and highlights the requirement of mechanism-directed, biomarker-based translational approaches. Further development in therapeutic vaccination may unravel its potential in personalized therapeutics.

Acknowledgement

None

Conflict of Interest

None

Grant Support & Funding Source

None

Use of Artificial Intelligence

The corresponding author declared that no artificial intelligence or AI-assisted tools were used in this manuscript.

Authors' Contribution

All authors contributed equally as per ICMJE.

References

1. Tian Y, Hu D, Li Y, Yang L. Development of therapeutic vaccines for the treatment of diseases. *Mol Biomed*. 2022;3(1):40. <https://doi.org/10.1186/s43556-022-00098-9>
2. Li J, Ross JL, Hambardzumyan D, Brat DJ. Immunopathology of glioblastoma. *Annu Rev Pathol*. 2026;21(1):135-162. <https://doi.org/10.1146/annurev-pathmechdis-042524-025950>
3. Singha SP, Memon S, Bano U, Isaac AD, Shahani MY. Evaluation of p21 expression and related autism-like behavior in Bisphenol-A exposed offspring of Wistar albino rats. *Birth Defects Res*. 2022;114(11):536–50. <https://doi.org/10.1002/bdr2.2022>
4. Weerathna IN, Doelakeh ES, Kiwanuka L, Kumar P, Arora S. Prophylactic and therapeutic vaccine development: advancements and challenges. *Mol Biomed*. 2024;5(1):57. <https://doi.org/10.1186/s43556-024-00222-x>
5. Maier JA, Castiglioni S, Petrelli A, Cannatelli R, Ferretti F, Pellegrino G, et al. Immune-mediated inflammatory diseases and cancer: a dangerous liaison. *Front Immunol*. 2024;15:1436581. <https://doi.org/10.3389/fimmu.2024.1436581>
6. Bano U, Memon S, Shahani MY, Shaikh P, Gul S. Epigenetic effects of in utero bisphenol A administration: Diabetogenic and atherogenic changes in mice offspring. *Iran J Basic Med Sci*. 2019;22(5):521–8. <https://doi.org/10.22038/ijbms.2019.29909.7357>
7. Memon S, Bano U, Shahani MY. Maternal exposure to Bisphenol-A induces epigenetic changes in metabolic syndrome markers of offspring. *FASEB J*. 2018;32(Suppl 1):774–2. https://doi.org/10.1096/fasebj.2018.32.1_supplement.774.2
8. Carabelli AM, Peacock TP, Thorne LG, Harvey WT, Hughes J, Peacock SJ, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. *Nat Rev Microbiol*. 2023;21(3):162-177. <https://doi.org/10.1038/s41579-022-00841-7>
9. Baharom F, Hermans D, Delamarre L, Seder RA. Vax-Innate: improving therapeutic cancer vaccines by modulating T cells and the tumour microenvironment. *Nat Rev Immunol*. 2025;25(3):195-211. <https://doi.org/10.1038/s41577-024-01091-9>
10. Corrado M, Pearce EL. Targeting memory T cell metabolism to improve immunity. *J Clin Invest*. 2022;132(1). <https://doi.org/10.1172/JCI148546>
11. Bretscher PA. The problem of host and pathogen genetic variability for developing strategies of universally efficacious vaccination against and personalised immunotherapy of tuberculosis: potential solutions? *Int J Mol Sci*. 2023;24(3):1887. <https://doi.org/10.3390/ijms24031887>
12. Tufail M, Jiang CH, Li N. Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. *Signal Transduct Target Ther*. 2025;10(1):227. <https://doi.org/10.1038/s41392-025-02280-1>
13. Butterfield LH, Najjar YG. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. *Nat Rev Immunol*. 2024;24(6):399-416. <https://doi.org/10.1038/s41577-023-00973-8>
14. Waugh S, Cameron CE. Syphilis vaccine development: aligning vaccine design with manufacturing requirements. *Hum Vaccin Immunother*. 2024;20(1):2399915. <https://doi.org/10.1080/21645515.2024.2399915>
15. Kaczmarek M, Poznańska J, Fechner F, Michalska N, Paszkowska S, Napierała A, et al. Cancer vaccine therapeutics: limitations and effectiveness—a literature review. *Cells*. 2023;12(17):2159. <https://doi.org/10.3390/cells12172159>
16. Wang S, Liang B, Wang W, Li L, Feng N, Zhao Y, et al. Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. *Signal Transduct Target Ther*. 2023;8(1):149. <https://doi.org/10.1038/s41392-023-01408-5>
17. Gomase VS, Sharma R, Dhamane SP. Immunoinformatics approach for optimization of targeted vaccine design: new paradigm in clinical trials and healthcare management. *Rev Recent Clin Trials*. 2025;Jul 16. <https://doi.org/10.2174/0115748871374235250702065617>
18. Wilson-Welder JH, Torres MP, Kipper MJ, Mallapragada SK, Wannemuehler MJ, Narasimhan B, et al. Vaccine adjuvants: current challenges and future approaches. *J Pharm Sci*. 2009;98(4):1278-316. <https://doi.org/10.1002/jps.21523>
19. Lin P, Lin Y, Mai Z, Zheng Y, Zheng J, Zhou Z, et al. Targeting cancer with precision: strategical insights into TCR-engineered T cell therapies. *Theranostics*. 2025;15(1):300-323. <https://doi.org/10.7150/thno.104594>

